Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Report Description

This report on the non-small cell lung cancer (NSCLC) Therapeutics market studies the current and future prospects of the global market. Non-small cell lung cancer is a type of lung cancer which accounted 85-90% of all lung cancers. There are three major subtypes of NSCLC namely squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC is relatively insensitive to chemotherapy compared to small cell lung cancer. Increasing awareness along with incidence rate are expected to propel the global non-small cell lung cancer therapeutics market.

The NSCLC market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global NSCLC therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global NSCLC therapeutics market.

Based on drug class, the NSCLC therapeutics market has been segmented into six major categories: angiogenesis inhibitor, epidermal growth factor receptor blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/ PD-L1 inhibitor. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global NSCLC therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, China, and Rest of Asia Pacific), and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global NSCLC therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.

The global non-small cell lung cancer therapeutics market is segmented as follows:

  • Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)
    • Overview
    • Angiogenesis Inhibitor
      • Avastin (bevacizumab)
      • Cyramza (Ramucirumab)
    • Epidermal Growth Factor Receptor Blocker
      • Tarceva (erlotinib)
      • Gilotrif (afatinib)
      • Iressa (gefitinib)
    • Kinase Inhibitor
      • Xalkori (crizotinib)
      • Zykadia (ceritinib)
    • Microtubule Stabilizer
      • Abraxane (paclitaxel protein bound)
      • Docetaxel
    • Folate Antimetabolites
      • Alimta (pemetrexed)
    • PD-1/ PD-L1 Inhibitor
      • Opdivo (nivolumab)
      • Keytruda (pembrolizumab)
  • Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics Market
    • Overview
    • Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)
      • Avelumab - Pfizer, Inc.
      • MPDL3280A - Roche
      • MEDI4736 - AstraZeneca
      • Abemaciclib - Eli Lilly and Company
      • Others
    • Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)
  • Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)
    • Overview
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Rest of Europe
    • Asia Pacific
      • Japan
      • China
      • Rest of Asia Pacific
    • Rest of the World

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote